文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

双抗原靶向即用型NK细胞在淋巴瘤和白血病中显示持久缓解并防止抗原逃逸

Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia.
PubMed 文献 · Blood · 2022-01-01

为克服抗原逃逸和异质性,研究者构建了表达NK优化抗CD19 CAR、高亲和力不可切割CD16及膜结合IL-15/IL-15R融合蛋白的诱导多能干细胞来源NK细胞(iDuo NK细胞)。体外和异种移植模型显示iDuo NK细胞具有强效抗淋巴瘤活性,可清除CD19阳性和CD19阴性淋巴瘤细胞,且优先靶向恶性细胞而非表达CD19的健康细胞,与治疗性抗体联用有望预防B细胞恶性肿瘤患者因抗原丢失和肿瘤异质性导致的复发。

要点

  • iDuo NK细胞同时表达抗CD19 CAR、高亲和力不可切割CD16和膜结合IL-15/IL-15R融合蛋白。
  • iDuo NK细胞在体外和异种移植模型中显示强效抗淋巴瘤活性,可清除CD19阳性和CD19阴性淋巴瘤细胞。
  • iDuo NK细胞优先靶向恶性细胞而非表达CD19的健康细胞,此特性抗CAR19 T细胞不具备。

核心结论

  • iDuo NK细胞与治疗性抗体联用是预防B细胞恶性肿瘤患者因抗原丢失和肿瘤异质性导致复发的一种有前景的方法。

研究设计与样本

  • 研究构建了诱导多能干细胞来源的NK细胞,表达NK细胞优化的抗CD19 CAR、高亲和力不可切割CD16及膜结合IL-15/IL-15R融合蛋白,称为iDuo NK细胞。
  • 在多个体外实验和异种移植过继转移模型中评估iDuo NK细胞的抗淋巴瘤活性。

主要发现

  • iDuo NK细胞显示强效CAR介导的细胞毒活性,靶向B细胞恶性肿瘤的治疗性抗体可进一步增强该活性。
  • 在多个体外和异种移植过继转移模型中,iDuo NK细胞表现出强效抗淋巴瘤活性。
  • iDuo NK细胞有效清除CD19阳性和CD19阴性淋巴瘤细胞。
  • iDuo NK细胞对恶性细胞表现出优先于表达CD19的健康细胞的靶向倾向,此特性抗CAR19 T细胞不具备。

临床怎么用

  • 原文结论认为iDuo NK细胞与治疗性抗体联用是预防B细胞恶性肿瘤患者因抗原丢失和肿瘤异质性导致复发的一种有前景的方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Substantial numbers of B cell leukemia and lymphoma patients relapse due to antigen loss or heterogeneity after anti-CD19 chimeric antigen receptor (CAR) T cell therapy. To overcome antigen escape and address antigen heterogeneity, we engineered induced pluripotent stem cell-derived NK cells to express both an NK cell-optimized anti-CD19 CAR for direct targeting and a high affinity, non-cleavable CD16 to augment antibody-dependent cellular cytotoxicity. In addition, we introduced a membrane-bound IL-15/IL-15R fusion protein to promote in vivo persistence. These engineered cells, termed iDuo NK cells, displayed robust CAR-mediated cytotoxic activity that could be further enhanced with therapeutic antibodies targeting B cell malignancies. In multiple in vitro and xenogeneic adoptive transfer models, iDuo NK cells exhibited robust anti-lymphoma activity. Furthermore, iDuo NK cells effectively eliminated both CD19+ and CD19- lymphoma cells and displayed a unique propensity for targeting malignant cells over healthy cells that expressed CD19, features not achievable with anti-CAR19 T cells. iDuo NK cells combined with therapeutic antibodies represent a promising approach to prevent relapse due to antigen loss and tumor heterogeneity in patients with B cell malignancies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cichocki F, Goodridge JP, Bjordahl R, et al. Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. Blood. 2022. PMID: 35917442. doi:10.1182/blood.2021015184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。